Immunohistochemical analysis of 35 NB clinical samples showed that the IGF2BP3 level in MYCN-amplified samples was higher than that in non-MYCN-amplified samples (Fig. 2A, B). This evidence concerns the gene IGF2BP3 and neuroblastoma.